Clopidogrel: Difference between revisions
| Line 23: | Line 23: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*bleeding, severe, | |||
*hemorrhage | |||
*TTP | |||
*agranulocytosis | |||
*hypersensitivity rxn | |||
*anaphylactoid rxn | |||
*Stevens-Johnson syndrome | |||
*toxic epidermal necrolysis | |||
*erythema multiforme | |||
*drug rash w/ eosinophilia and systemic sx | |||
*pneumonia, eosinophilic | |||
===Common=== | ===Common=== | ||
Revision as of 23:08, 26 June 2015
General
- Type: Antiplatelet
- Dosage Forms: 75, 300 PO
- Common Trade Names: Plavix
Adult Dosing
Pediatric Dosing
Special Populations
- Pregnancy Rating:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- bleeding, severe,
- hemorrhage
- TTP
- agranulocytosis
- hypersensitivity rxn
- anaphylactoid rxn
- Stevens-Johnson syndrome
- toxic epidermal necrolysis
- erythema multiforme
- drug rash w/ eosinophilia and systemic sx
- pneumonia, eosinophilic
Common
Pharmacology
- Half-life: 8h
- Metabolism: liver, CYP450: 1A2, 2C9, 2C19 (primary), 3A4 substrate
- Excretion: urine 50%, feces 46%
- Mechanism of Action: irreversibly binds to P2Y12 adenosine diphosphate receptors, reducing platelet activation and aggregation